Anti-fibrogenic effects of cathelicidin in chronic colitis.

**Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis.**

Jun Hwan Yoo\(^1,3\), Samantha Ho\(^1\), Deanna Hoang-Yen Tran\(^1\), Michelle Cheng\(^1\), Kyriaki Bakirtzi\(^1\), Yuzu Kukota\(^1\), Ryan Ichikawa\(^1\), Bowei Su\(^1\), Diana Hoang-Ngoc Tran\(^1\), Tressia C. Hing\(^1\), Irene Chang\(^1\), David Q Shih\(^5\), Richard E. Issacson\(^6\), Richard L. Gallo\(^2\), Claudio Fiocchi\(^4\), Charalabos Pothoulakis\(^1\), and Hon Wai Koon\(^1\).

**Author affiliation:**

1 Inflammatory Bowel Disease Center, Division of Digestive Diseases, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA.

2 Division of Dermatology, University of California San Diego, San Diego, CA 92093, USA.

3 Digestive Disease Center, CHA University Bundang Medical Center, Seongnam 463-712, Republic of Korea.

4 Department of Pathobiology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

5 F. Widjaja Foundation, Inflammatory Bowel & Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

6 Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA.

**Involvement of authors:**

Jun Hwan Yoo, Samantha Ho and Hon Wai Koon---acquisition, analysis and interpretation of data; drafting of the manuscript
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Ryan Ichikawa, Michelle Cheng, Yuzu Kubota, Deanna H.Y. Tran, Bowei Su, Diana H.N. Tran, Tressia C Hing, Irene Chang, David Q Shih --- acquisition of data
Richard Issacson, Kyriaki Bakirtzi, Richard L Gallo --- provision of materials and services
Claudio Fiocchi --- provision of materials, interpretation of data, and editing manuscript
Charalabos Pothoulakis --- critical revision of manuscript and study supervision.

Short Title: Anti-fibrogenic effects of cathelicidin in chronic colitis.

Grant support: This work was supported by Pilot and Feasibility Study grant from the UCLA-CURE Center, Crohn’s and Colitis Foundation of America Research Fellowship (#1406), Career Development Award (#2691) and NIH K01 DK084256 grant to HWK, Crohn’s and Colitis Foundation of America student research fellowship (#287244, #3831 & #324000) to MC and SH and Deanna Tran, and DK50984 to CF. Support was also provided by the Blinder Research Foundation for Crohn’s Disease, the Eli and Edythe Broad Chair (CP), and United States Public Health Service Grant DK072471 (CP).

Disclosure: All authors have nothing to disclose. No conflicts of interest exist.

Corresponding Author:
Hon Wai Koon, Ph.D.
Inflammatory Bowel Disease Center, Division of Digestive Diseases,
David Geffen School of Medicine, MRL Building, Room 1519
675 Charles E. Young Dr. South, Los Angeles, CA 90095
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Office phone: 310-825-9742, Fax: 310-825-3542; E-mail: hkoon@mednet.ucla.edu

32 pages text, 15 figures, 1 supplementary figures and 1 supplementary figure legend.

Word counts: 2421

Synopsis:
Administration of cathelicidin exerts effective anti-fibrogenic effects in colitis associated intestinal fibrosis. Cathelicidin inhibits transforming growth factor beta 1 induced collagen expression in fibroblasts. The anti-fibrogenic effect is extracellular-regulated kinase pathway dependent.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Abstract:

**Background and Aims:** Cathelicidin (LL-37 in human and mCRAMP in mice) represents a family of endogenous antimicrobial peptides with anti-inflammatory effects. LL-37 also suppresses collagen synthesis, an important fibrotic response, in dermal fibroblasts. Here we determined whether exogenous cathelicidin administration modulates intestinal fibrosis in two animal models of intestinal inflammation and in human colonic fibroblasts. **Methods:** C57BL/6J mice (n=6 per group) were administered intracolonomically with a trinitrobenzene sulphonic acid (TNBS) enema to induce chronic (6-7 weeks) colitis with fibrosis. mCRAMP peptide (5 mg/kg every 3 day, week 5-7) or cathelicidin gene (**Camp**)-expressing lentivirus (10^7 infectious units week 4) were administered intracolonomically or intravenously, respectively. 129Sv/J mice were infected with *Salmonella typhimurium* orally to induce cecal inflammation with fibrosis. **Camp** expressing lentivirus (10^7 infectious units day 11) was administered intravenously. **Results:** TNBS-induced chronic colitis was associated with increased colonic collagen (col1a2) mRNA expression. Intracolomic cathelicidin (mCRAMP peptide) administration or intravenous delivery of lentivirus-overexpressing cathelicidin gene significantly reduced colonic col1a2 mRNA expression in TNBS-exposed mice, compared to vehicle administration. *Salmonella* infection also caused increased cecal inflammation associated with collagen (col1a2) mRNA expression that was prevented by intravenous delivery of **Camp**-expressing lentivirus. Exposure of human primary intestinal fibroblasts and human colonic CCD-18Co fibroblasts to transforming growth factor-beta1 (TGF-beta1) and/or insulin-like growth factor 1 induced collagen protein and mRNA expression, that was reduced by LL-37 (3-5 μM) through a MAP kinase-dependent mechanism. **Conclusion:** Cathelicidin can reverse intestinal fibrosis by directly inhibiting collagen synthesis in colonic fibroblasts.

**Keywords:** Anti-microbial peptide, inflammatory bowel disease, collagen.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

**Introduction:**

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is manifested by chronic inflammation of the gastrointestinal tract with significant morbidity and at times, life-threatening complications. Patients with chronic CD often develop transmural luminal narrowing and form strictures caused by excessive extracellular matrix deposition. The mechanisms of intestinal fibrosis are complex and not well understood. Transforming growth factor-beta 1 (TGF-β1) levels are often higher in the mucosa overlying CD strictures, compared to non-strictured gut. Therapies for fibrosis are ineffective and surgical resection is often required. Approximately 75% of CD patients eventually undergo surgery, most frequently due to intestinal fibrosis. Therapy with anti-TNFα monoclonal antibodies can effectively reduce inflammation, but may not prevent or reverse fibrosis in CD patients. Previous studies also showed that inhibition of TGF-β1 reduces colonic fibrosis in a mouse chronic colitis model.

Cathelicidins (LL-37 in humans and mCRAMP in mice) represent a family of endogenous anti-microbial peptides mediating part of the innate immune response that protects the host from infection. Several studies support the importance of cathelicidins in the pathogenesis of various disease states. Cathelicidin deficient (Camp−/−) mice are more susceptible to infections, and have reduced angiogenesis and wound healing. Park et al also showed that LL-37 reduces collagen synthesis in dermal fibroblasts, suggesting a potential role for cathelicidins in reducing fibrosis. Intracolonic administration of mCRAMP reduces the severity of dextran sulfate (DSS)-mediated acute colitis in mice, while Camp−/− mice have exacerbated acute DSS-induced colitis. In addition, cathelicidin effectively reduces *C. difficile* mediated colitis and acute *C. difficile* toxin A-induced enteritis in mice. Despite its potent anti-inflammatory effects in acute colitis, the potential role of cathelicidin in the
Anti-fibrogenic effects of cathelicidin in chronic colitis.

development and progress of chronic colitis has not been explored and the possibility that cathelicidins
modulate intestinal fibrosis has never been studied.

Here we used the well established chronic TNBS induced colitis mouse model as well as the
Salmonella-mediated cecal inflammation model to study intestinal fibrosis associated with these
models. We found that intracolonic peptide or intravenous lentiviral administration of cathelicidin
attenuates colitis-associated intestinal fibrosis and inflammation in vivo. LL-37 reduces TGF-β1- and
IGF-1- induced collagen expression in human colonic fibroblasts in vitro. Our results also indicate that
reduced collagen expression in response to cathelicidin is mediated via ERK activation in these cells.

Materials and Methods:

Cell Cultures:

Human CCD-18Co colonic fibroblasts (2 x 10^6 cells/plate) were cultured in minimal essential
medium Eagle’s medium (ATCC, Manassas, VA) containing 10% fetal bovine serum (Invitrogen) and
1% penicillin/streptomycin (Invitrogen). Human primary normal intestinal fibroblasts (3 normal and
2 CD patients) were isolated as previously described. Cells (2 x 10^6 cells/plate) were cultured in
DMEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and serum starved
overnight before experiments. LL-37 peptide was purchased from Biopeptide Co., Inc (San Diego,
CA). TGF-β1, IGF-1, proinflammatory cytokine cocktail (TNFα, IL-1β and IFNγ, 10 ng/ml each),
U0126 and PD98059 were purchased from Fisher scientific, Pittsburgh, PA. LL-37, TGF-β1, IGF-1
and proinflammatory cytokine cocktail were dissolved in trifluoroacetic acid (TFA) 0.1% as vehicle
solution. PD98059 and U0126 were dissolved in DMSO. Human primary intestinal fibroblasts from
normal subjects and CD patients and cultured human colonic CCD-18Co fibroblasts responded to
Anti-fibrogenic effects of cathelicidin in chronic colitis.

TGF-β1 and/or IGF-1 differently. Based on preliminary experiments, we used two different conditions (TGF-β1 alone and TGF-β1 + IGF-1) to stimulate collagen expression. IGF-1 alone is not sufficient to induce collagen expression in all fibroblasts we used (data not shown).

**TNBS chronic colitis model:**

Camp−/− mice in C57BL/6J strain were obtained from Dr. Richard Gallo at the University of California, San Diego and were bred and maintained at the University of California, Los Angeles (UCLA) animal facility under standard environmental conditions. Animal studies were approved by animal research committee of UCLA. Chronic TNBS-associated colitis was induced as previously reported 14, 15. Mice (8-9 weeks old) were injected with TNBS solution or 30% ethanol (50 μL) intracolonically for 5 weeks as illustrated in Figure 1A. Intracolonic administration was achieved by inserting a PE10 catheter 3 cm into rectum under light isoflurane anesthesia. A group of mice were injected with 5 mg/kg mCRAMP intracolonically every 3 days starting at week 5. Another mouse group were injected with Camp-expressing lentivirus (1x10⁷ infectious units/mouse) or hemagglutinin (HA)-expressing lentivirus intravenously once, starting at week 5 as illustrated in Figure 6A. Colonic tissues were obtained at week 6 or 7 after carbon dioxide euthanasia.

**Salmonella infection model:**

Wild-type mice in 129Sv/J strain were obtained from Jackson Laboratories and maintained at the University of California, Los Angeles (UCLA) animal facility under standard environmental conditions. Each mouse was administered with 20 mg streptomycin by oral gavage. *Salmonella typhimurium* SL1344 strain was obtained from Dr. Richard Issacson (University of Minnesota) and cultured in LB broth for 48 hours. 24 hours later, the mice were given *Salmonella typhimurium*
Anti-fibrogenic effects of cathelicidin in chronic colitis.

SL1344 strain 1x10⁸ cfu or LB broth in 100 µl by oral gavage as previously described ¹³. Some groups were injected with Camp expressing lentivirus (1x10⁷ infectious units/mouse) or HA lentivirus intravenously once starting on day 11 as illustrated in Figure 8A. Cecal tissues were obtained on day 21 after carbon dioxide euthanasia.

*Virus production and transduction:*

The generation of cathelicidin expressing lentivirus was performed by UCLA vector core facility. Lentivirus-based vectors encoding CRAMP were generated by transient cotransfection of 293T cells with a three-plasmid combination, as described previously, with slight modifications ¹⁷. Briefly, 8 x T175 flasks of nonconfluent 293T cells were co-transfected with 39 µg pMDLg/pRRE, 21 µg of pMDG (encoding the VSV-G envelope), 15 µg of pRSV–REV and 60 µg pRRL-CMV-CRAMP-Ires GFP, by the CaPi-DNA coprecipitation method ¹⁸,¹⁹. The plasmid vectors were kindly provided by Dr Luigi Naldini (University of Torino, Italy). Next day, the medium was adjusted to make a final concentration of 10 mM sodium butyrate and the cells were incubated for 5 h to obtain high-titer virus production as previously described ²⁰. After the 5 h incubation, cells were washed and incubated in fresh medium without sodium butyrate. Conditioned medium was harvested 16 h later and passed through 0.45 mm filters. The harvested supernatant was transferred into a centrifuge tube and layered on top of a 10 ml 20% (w/v) sucrose cushion. The tubes were centrifuged using SW28 rotor (Beckman Coulter Incorporated, Brea, CA, USA) for 2 hours at 22,000 rpm at 4°C. The virus-containing pellet was resuspended by gentle agitation in an appropriate volume of DPBS, followed by a short centrifugation step 5 min at 16,000 g) to pellet debris. Finally, the opaque pellet was transferred to a new tube. The biological titer of the LVs carrying the eGFP reporter was analyzed by transduction of HEK 293T cells followed by flow cytometry and IP/ml were calculated as previously described ²¹.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Histological scoring:

Murine colonic tissues were fixed, sectioned and stained with H&E. Microphotographs at 200X magnification were recorded at multiple locations and analyzed by two investigators in a blinded manner that scored the specimens at a 0-12 scale for chronic TNBS colitis as previously described 22. Fibrosis score for both TNBS and Salmonella models was determined as previously described 23. In brief, several mucosal and submucosal locations of each Masson trichrome stained slides were evaluated on a 0-3 scale (0= no fibrosis, 1=mild fibrosis; 2=moderate fibrosis and 3 severe fibrosis).

Mouse TNF-α, mouse and human TGF-β1 ELISA:

The levels of mouse TNF-α (DY410), mouse TGF-β1 (DY1679) and human TGF-β1 (DY240) of R&D Systems (Minneapolis, MN) were measured by the enzyme-linked immunosorbent assay kits according to manufacturer’s instructions.

Quantitative real-time RT-PCR:

Total RNA was isolated by RNeasy kit (Qiagen, CA) and reversed transcribed into cDNA by a Superscript III kit (#11752, Invitrogen, Carlsbad, CA). Quantitative PCR reactions were run in an ABI Prism 7500 Fast sequence detector system as we previously described 15. The levels of mRNA were determined by using cataloged primers (Invitrogen) for human COL1A2 (Hs01028956_m1), CAMP (Hs00189038_m1), mouse vimentin (Mm01333430_m1), 18S (Hs99999901_s1) and mouse Col1a2 (Mm01309565_m1), Camp (Mm00438285_m1), Tgf-β1 (Mm01178820_m1), Tnfα (Mm00443259_g1) and Gapdh (Mm99999915_g1). Results were expressed as relative fold difference.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

**Masson Trichrome Staining:**

Staining of collagen deposition of colonic tissue sections was performed by Masson Trichrome staining kit (HT-10, Sigma, St. Louis, MO) and Bouin solution (HT-10132) as previously described 15.

**Immunofluorescence Staining:**

Frozen mouse colonic tissues were embedded in OCT solution and fixed in acetone. After incubation with blocking buffer, slides were incubated with primary antibodies including rabbit polyclonal anti-collagen sc-28655, rabbit polyclonal anti-PCNA sc-7907, or goat polyclonal anti-vimentin sc-7557 (1:50 dilution) for 2 hours at room temperature, washed with PBS and incubated with fluorescent conjugated secondary antibodies including donkey anti-rabbit Texas Red sc-2784 and bovine anti-goat FITC sc-2348 for 1 hour (1:100 dilution). Slides were then rinsed and mounted with 4,6-diamidino-2-phenylindole (DAPI) mounting solution. Images were analyzed with a AX10 confocal microscope (Carl Zeiss, Thornwood, NY).

**Immunohistochemistry:**

Colon tissues were fixed in 4% paraformaldehyde and embedded in paraffin. After incubation with blocking buffer, sections were incubated with a goat polyclonal anti-vimentin antibody (sc-7557, Santa Cruz biotechnology, Santa Cruz, CA, 1:50 dilution), a rabbit polyclonal anti-F4/80 antibody (sc-26643-R, Santa Cruz, 1:50 dilution) or a rabbit polyclonal anti-phospho-ERK antibody (#4370, Cell signaling, Danvers, MA, 1:50 dilution) overnight at 4°C. After washing, sections were incubated with donkey anti-goat IgG or bovine anti-rabbit IgG and slides were stained with an ABC kit for color development (Santa Cruz, sc-2018). Immunohistochemistry was assisted by Translational Pathology
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Core Laboratory (TPCL) of UCLA. Images were analyzed with a Zeiss AX10 microscope at magnification of 200X.

**Western Blot analyses:**

Cells were lysed in RIPA buffer with proteinase inhibitors cocktail (Cell signaling, Danvers, MA). Equal amounts of cell extracts were fractioned by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and proteins were transferred onto nitrocellulose membranes (400mA for 1.5 hours at 4°C; Bio-Rad, Hercules, CA, USA). Membranes were blocked in 5% nonfat milk in TBST (50mM Tris, pH 7.5, 0.15M NaCl, 0.05% Tween 20), and then incubated with antibodies against phospho-ERK #4370, β-tubulin #2146 (Cell Signaling), phospho-EGFR #sc12351 (Santa Cruz Biotechnology, Santa Cruz, CA), pro-COL1A1 #SP1D8 (Development Studies Hybridoma Bank, Iowa City, IA). Horseradish peroxidase-labeled antibodies were detected by chemiluminescence (Fisher Scientific, Pittsburgh, PA, USA) and signals were captured using the luminescent image analyzer LAS4000 (Fujifilm, Tokyo, Japan).

**Statistical Analyses:**

Results were expressed as mean +/- SEM and analyzed by using the Prism professional statistics software program (Graphpad, San Diego, CA). Unpaired Student’s t-tests were used for intergroup comparisons. \( p \) values of significant difference are shown in each figure.

**Results:**

*Cathelicidin reduces chronic, TNBS-induced colitis in mice.*
Anti-fibrogenic effects of cathelicidin in chronic colitis.

We have previously shown that cathelicidins have anti-inflammatory effects against DSS-induced colitis and *C. difficile* infection in mice \(^{11,12}\). To investigate the role of cathelicidin in chronic colitis, mice were administered a low dose of TNBS intracolonically every week as previously described \(^{14,15}\). The experimental design of these experiments is illustrated in Figure 1A. After 7 weeks, body weight of TNBS-treated mice was significantly lower (p=0.045) compared to that of ethanol-treated (control) mice (Figure 1B). Intracolonic administration of the mCRAMP peptide to TNBS-exposed mice restored body weight loss to levels similar to those of control mice (p=0.0178, Figure 1B). Moreover, chronic TNBS administration induced colonic tissue damage with significantly higher (p=0.001) histological scores compared to damage induced in control mice (Figure 1C and 1D). Intracolonic mCRAMP administration significantly reduced the colonic histology score (p=0.03) in TNBS-treated mice (Figures 1D).

TNBS caused a significant increase of the colonic proinflammatory cytokine tumor necrosis factor alpha (Tnfa) mRNA levels (p=0.0344, Figure 1E), which were significantly reduced by mCRAMP administration (p=0.046, Figure 1E). Intracolonic TNBS also increased colonic Tgf-β1 mRNA expression, but intracolonic administration of cathelicidin did not alter this response (Figure 1F). However, intracolonic mCRAMP did not change the increased colonic F4/80 positive macrophage infiltration in TNBS-treated mice (Figure 2). Thus, intracolonic administration of cathelicidin reduces chronic experimental colitis in an IBD mouse model, consistent with our results in the *C. difficile* infection model of colitis \(^{12}\).

*Cathelicidin reduces chronic colitis-associated collagen expression.*
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Intestinal fibrosis with stricture formation is an important complication in CD patients. We next evaluated the effect of intracolonic cathelicidin in TNBS colitis-associated colonic fibrosis with Masson trichrome staining for collagen formation. We found increased collagen deposition in the colon of TNBS-treated mice, both in the mucosa and submucosa compared to control mice (Figure 3A), in line with previous observations. Increased fibrosis was also reflected by an increased fibrosis score (Figure 3B). Moreover, compared to ethanol treatment, chronic TNBS administration increased collagen Col1a2 mRNA colonic expression (p=0.0376, Figure 3C) that was significantly reduced by intracolonic mCRAMP administration (p=0.0364, Figure 3C), suggesting anti-fibrogenic effects. Double immunofluorescence staining showed increased colonic collagen protein expression in and around vimentin-expressing fibroblasts in TNBS-treated mice (Figure 4). Co-localization of collagen and vimentin indicates that fibroblasts are main sources of collagen expression. Intracolonic mCRAMP peptide administration also reduced collagen expression in and around colonic fibroblasts of TNBS-treated mice (Figure 4).

On the other hand, cathelicidin deficient mice showed similar colonic histologic damage (Figure 5A and 5B), collagen expression (Figure 5C and 5D), or TNFα protein levels (Figure 5E) as wild type mice in chronic TNBS colitis. Our data also indicates that expression of endogenous colonic cathelicidin in wild type mice was not induced during chronic TNBS colitis (Figure 6B). However, intracolonic cathelicidin mCRAMP administration reduced colonic tissue damage (Figure 5A and 5B) and exerted anti-fibrogenic effects in TNBS-treated Camp⁻/⁻ mice (Figure 5C and 5D).

*Lentiviral expression of cathelicidin reduces colitis associated intestinal fibrosis.*
Anti-fibrogenic effects of cathelicidin in chronic colitis.

To further examine the effects of cathelicidin in colitis-associated fibrosis, we injected intravenously cathelicidin-overexpressing lentiviruses and determined their effects in the chronic TNBS-associated model of colitis and colonic fibrosis using the experimental approach shown in Figure 6A. We found that intravenous administration of cathelicidin-expressing lentiviruses increased colonic cathelicidin mRNA levels compared to injection of control lentiviruses (Figure 6B). Moreover, injection of cathelicidin-overexpressing lentiviruses significantly reduced histological damage and histology score in response to chronic TNBS administration (Figure 6C & 6D) without affecting body weight changes in response to TNBS (Figure 6E). Lentiviral overexpression of cathelicidin also inhibited TNBS-induced collagen deposition in the colon, as reflected by a significant reduction in the colonic fibrosis score (p=0.0001, Figure 7A and 7B), and reduced colonic collagen Col1a2 mRNA expression (p=0.0497, Figure 7C).

**Lentiviral expression of cathelicidin reduces cecal fibrosis during Salmonella infection**

*Salmonella* induces intestinal inflammation and fibrosis in a TH1 and TH17-dependent manner. We therefore next examined whether injection of lentivirus-overexpressing cathelicidin has any effect on *Salmonella*-induced fibrosis using the experimental design shown in Figure 8A. Interestingly, *Salmonella* infection by itself resulted in increased mRNA levels of cecal cathelicidin (p=0.0001, Figure 8B), which was further increased by injection of cathelicidin expressing lentiviruses in the inflamed cecum (p=0.0317, Figure 8B). As shown by H&E staining, *Salmonella* caused severe cecal inflammation and tissue damage that was reduced by lentiviral cathelicidin expression (Figure 8C and Figure 8D). Cathelicidin overexpressing lentiviruses also significantly reduced *Salmonella*-induced proinflammatory cytokine Tnfa mRNA expression (p=0.0107) (Figure 8E). No change in body weight was observed in any of the *Salmonella*-infected groups (Figure 9A).
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Masson trichrome staining indicated strong cecal collagen deposition in *Salmonella*-infected mice, which was diminished by lentiviral cathelicidin overexpression (Figure 9B), reflected by a significant reduction in fibrosis score (p=0.0001, Figure 9C) and cecal collagen mRNA expression (p=0.0251, Figure 9D). Overexpression of cathelicidin in *Salmonella*-infected mice did not significantly affect cecal Tgf-β1 mRNA expression (Figure 9E).

*Cathelicidin inhibits TGF-β1 and IGF-1 induced collagen expression in human intestinal fibroblasts.*

In the mucosa of CD strictures, TGF-β1 and IGF-1 stimulates collagen expression in intestinal fibroblasts, leading to fibrosis. Previous studies indicated that TGF-β1 stimulates collagen synthesis in lung and dermal fibroblasts. To study the anti-fibrogenic mechanism of cathelicidin, we co-incubated human primary normal intestinal fibroblasts with TGF-β1 (5 ng/ml) together with human cathelicidin (LL-37, 5 µM). TGF-β1 alone stimulated procollagen 1A1 protein expression (p=0.0001) in human primary normal intestinal fibroblasts after 48 hours (Figure 10A and 10B). Co-incubation with human cathelicidin significantly reduced TGF-β1-stimulated (p=0.0001) procollagen 1A1 protein expression (Figure 10A and 10B). Similarly, LL-37 significantly inhibited TGF-β1 stimulated COL1A2 mRNA expression in human primary intestinal fibroblasts (Figure 10C) and also reduced procollagen 1A1 protein expression induced by TGF-β1 in human primary intestinal fibroblasts isolated from CD patients (Figure 10D and 10E). Moreover, in cultured human colonic CCD-18Co fibroblasts, cathelicidin inhibited TGF-β1- and/or IGF-1-induced collagen protein synthesis (Figure 11).

*Cathelicidin reduces collagen expression in human colonic fibroblasts via ERK activation.*
Anti-fibrogenic effects of cathelicidin in chronic colitis.

ERK activation has been shown to be involved in the anti-fibrogenic effects of cathelicidin in dermal fibroblasts. We hypothesized that ERK may represent a pathway modulating the anti-fibrogenic effects of cathelicidin in primary intestinal fibroblasts. We found that LL-37-induced inhibition of TGF-β1-mediated collagen protein expression in human primary normal intestinal fibroblasts was partially reversed by pretreatment of cells with the ERK inhibitors PD98059 and U0126 (Figure 12A). Moreover, cathelicidin induced ERK phosphorylation in a concentration dependent manner regardless of the presence of TGF-β1 or IGF-1 in human normal primary intestinal fibroblasts (Figure 12B). Consistent with these findings, cathelicidin induced ERK phosphorylation (addition of EGF serving as a positive control), but not EGFR phosphorylation in human CCD-18Co colonic fibroblasts (Figure 13A). Addition of EGF also augmented the anti-fibrogenic effects of cathelicidin in both human primary intestinal fibroblasts obtained from CD patients and human CCD-18Co colonic fibroblasts (Figure 13B-E). These results suggest that cathelicidin inhibits fibrogenesis via an ERK-dependent pathway in native human colonic fibroblasts.

To confirm cathelicidin mediated ERK activation in vivo, we determined ERK phosphorylation in submucosal tissues of colons and cecum where most fibroblasts are populated. We found the submucosal tissues of normal, TNBS treated or *Salmonella* infected mice had low expression of phosphorylated ERK (Supplementary Figure 14A and 14B). Both intracolonic mCRAMP peptide administration and intravenous *Camp*-expressing lentivirus administration activated colonic or cecal ERK phosphorylation in TNBS or *Salmonella* model of intestinal fibrosis (Figure 14A and 14B).

**Discussion:**
Anti-fibrogenic effects of cathelicidin in chronic colitis.

We and others have previously shown that the antimicrobial peptide cathelicidin possesses potent anti-inflammatory activities against acute intestinal inflammation \(^{10-12}\). Consistent with these findings, our results using the models of chronic TNBS colitis and *Salmonella* infection and two different approaches, i.e. intracolonic administration of cathelicidin peptide and intravenous injection of cathelicidin-expressing lentiviruses, demonstrate that cathelicidin exerts significant anti-inflammatory effects, including reduction of mucosal Tnf\(\alpha\) protein or mRNA expression (Figure 1E, 5E and 8E). Both approaches also lead to substantial improvement of histologic evidence of colitis in both animal models (Figure 1D, 5B, 6D and Figure 8D). Taken together with previous findings \(^{10-12}\), our results demonstrate a role for exogenous administration of cathelicidin against both acute and chronic IBD-related colitis as well as infectious colitis of different etiologies. Most importantly, we report here that cathelicidin inhibits colitis-associated colonic fibrosis in chronic TNBS and *Salmonella* infection models *in vivo* and in human intestinal fibroblasts *in vitro*, suggesting that exogenous cathelicidin may represent an effective approach in inhibiting colitis-associated fibrosis.

The role of antimicrobial peptides or proteins, including cathelicidins, in colitis associated intestinal fibrosis or stricture formation has never been reported. We report here that cathelicidin inhibits colitis-associated colonic fibrosis *in vivo* and substantially reduces TGF-\(\beta\)1- and/or IGF-1-mediated collagen protein synthesis in human intestinal fibroblasts isolated from three normal subjects and two CD patients (Figure 10A-E) as well as in human colonic CCD-18Co fibroblasts (Figure 11).

In rats, systemic blockade of putative cathelicidin receptor P2X7 by A740003 and brilliant blue G prevented TNBS induced colitis \(^{25}\) while another P2X7 inhibitor, A438079 reduced mouse liver fibrosis \(^{26}\). Another putative cathelicidin receptor FPRL1 was found to mediate LL-37-induced
Anti-fibrogenic effects of cathelicidin in chronic colitis.

collagen production in human lung fibroblasts. However, the anti-fibrogenic effect of LL-37 in human intestinal fibroblasts was not altered by pretreatment with the FPRL1 antagonist WRW4 or the P2X7 antagonist KN62 (data not shown), suggesting that the anti-fibrogenic effects of cathelicidin do not depend on these two putative cathelicidin receptors.

This anti-fibrogenic effect likely involves an ERK-dependent mechanism as it can be blocked by the MEK1 inhibitor PD98059 and the MEK1/2 inhibitor U0126 (Figure 12A). Cathelicidin induces ERK phosphorylation in human normal intestinal fibroblasts and human CCD-18Co colonic fibroblasts (Figure 12B and Figure 13A). Specifically, the effects of cathelicidin in collagen synthesis appear to be mediated by MEK1, as the MEK1 inhibitor PD98059 was sufficient to reverse LL-37-mediated suppression of TGF-β1- induced collagen synthesis (Figure 12A). These results confirm that the anti-fibrogenic effects of cathelicidin in intestinal fibroblasts are ERK-dependent and are consistent with a previous report demonstrating that the anti-fibrogenic mechanism of cathelicidin in dermal fibroblasts involves ERK activation.

Cathelicidin did not affect protein expression of the fibrogenic TGF-β1 in CCD-18Co colonic fibroblasts, even in the presence of a proinflammatory cytokine cocktail (TNFα, IL-1β and IFNγ) (Figure 15A and 15B). Moreover, intracolonic cathelicidin administration or injection of cathelicidin-overexpressing lentiviruses did not affect intestinal TGF-β1 mRNA expression in both TNBS and Salmonella fibrosis mouse models (Figure 1F and 9E). These results suggest that the anti-fibrogenic effects of cathelicidin are independent of the classical TGF-β1-mediated pro-fibrogenic events.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

On the other hand, cathelicidin treatment did not induce fibroblast cell proliferation \textit{in vitro}, and did not affect colonic or cecal expression of the fibroblast marker vimentin expression (data not shown) and PCNA staining (Supplementary Figure) in our \textit{in vivo} models. We did not observe colonic apoptosis (TUNEL assay) following intracolonic or intravenous cathelicidin administration (data not shown), suggesting that cathelicidin is unlikely to cause tissue damage in the intestine.

Despite the positive anti-fibrogenic effects of cathelicidin administration, TNBS treated cathelicidin deficient mice did not show additional colonic fibrosis or tissue damage, compared to TNBS treated wild-type mice (Figure 5). The lack of increased endogenous cathelicidin expression (Figure 6B) may be related to low levels of inflammation seen in this chronic TNBS-induced model as reflected by low colonic TNF\(\alpha\) protein level (Figure 5E). Colonic TNF\(\alpha\) levels were similar among TNBS treated wild-type and \textit{Camp}\(^+/-\) mice (Figure 5E). Although colonic cathelicidin mRNA expression is increased in acute DSS-induced colitis \textsuperscript{11}, intestinal cathelicidin mRNA expression is not altered in CD patients \textsuperscript{28}.

Several studies underlined the importance of the bacterial composition of the intestinal flora, in IBD pathophysiology and epithelial barrier integrity. Along these lines, the ability of cathelicidin to alter the gut microflora may be associated with the anti-fibrogenic effects reported here \textsuperscript{10,11}. Since the microflora composition associated with intestinal fibrosis has not been identified in animal or human colon, future studies are necessary to explore this possibility.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

In summary, our report provides novel evidence for an anti-fibrogenic effect of cathelicidin *in vivo* and *in vitro*. Our results strongly suggest that cathelicidin administration may be a novel approach to prevent or treat IBD, and IBD-related colonic fibrosis.

**Acknowledgements:** The cathelicidin expressing lentivirus was produced by the UCLA Vector Core, supported by JCCC/P30 CA016042 and CURE/P30 DK041301.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

**Figure legends:**

**Figure 1**

*Cathelicidin peptide administration reduces colonic inflammation in TNBS mediated chronic colitis in mice.*

(A) Illustration of experimental plan of TNBS-mediated chronic colitis. Mice were injected with increasing doses of TNBS solution intracolonically once a week for 6 weeks. Some mice received intracolonic injection of mCRAMP peptide or vehicle solution 0.1% of trifluoroacetic acid (control), starting from the fifth TNBS injection. Colonic changes were evaluated 2 weeks after the last TNBS injection. (B) Percent of body weight change of different groups (from week 0 to week 7). All ethanol treated groups had approximately 20% body weight gain. TNBS treated wild-type mice suffered from significantly less body weight gain, compared to ethanol control (p=0.045). Administration of mCRAMP peptide to TNBS treated wild-type partially restored the body weight gain (p=0.0178). (C) Representative H&E images of colonic tissues. Large arrows show immune cell infiltration. Small arrows show collagen deposition and mucosal transformation with altered cryptal architecture. (D) Histology score was based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue damage with significantly higher histology score (p=0.001), compared to ethanol control. Treatment with mCRAMP significantly reduced histology score (p=0.03). (E) TNBS treatment significantly induced colonic proinflammatory cytokine Tnfa mRNA (p=0.0344) expression. Intracolonic mCRAMP administration significantly reduced TNBS induced mRNA (p=0.046) expression in mice. (F) Colonic Tgf-β1 mRNA expression in mice with chronic TNBS colitis. Colonic Tgf-β1 mRNA expression was not affected by intracolonic mCRAMP peptide administration. n=6 mice per group.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

Figure 2

**Cathelicidin administration does not affect macrophage infiltration in colonic tissues.**

Immunohistochemistry of macrophage marker F4/80 in colonic tissues. Macrophages are identified by brown staining as indicated by arrows. TNBS treated mice had increased F4/80 immunostaining, compared to ethanol control group. Intracolonic mCRAMP treatment did not affect F4/80 expressing macrophage infiltration in TNBS treated mice.

Figure 3

**Cathelicidin peptide administration reduces colonic collagen deposition in mice with chronic TNBS colitis.**

(A) Masson Trichrome staining for collagen in colonic tissues. Collagen was stained in blue with a red background. Collagen deposited in mucosal and submucosal layer of TNBS treated mice was reduced by mCRAMP peptide treatment. (B) Fibrosis score of colonic tissues. The elevated fibrosis score of TNBS treated mice (p=0.0001) was significantly reduced by mCRAMP peptide treatment (p=0.0001). (C) Quantitative real-time RT-PCR of collagen col1a2 mRNA expression in colonic tissues of mice. TNBS treatment significantly induced colonic col1a2 mRNA (p=0.0376) expression. Intracolonic treatment of mCRAMP reduced colonic col1a2 mRNA expression (p=0.0364). n=6 mice per group.

Figure 4

**Cathelicidin reduces collagen expression in colonic fibroblasts.**

Immunofluorescence staining of collagen (red), fibroblast marker vimentin (green) and nuclei DAPI (blue). In TNBS+TFA, intense red collagen staining was observed in and around fibroblasts that were identified by green color. Overlapping images of red collagen staining and green vimentin staining
Anti-fibrogenic effects of cathelicidin in chronic colitis.

resulted in yellowish color (lower right corner), indicating co-localization of collagen expression in fibroblasts. TNBS+mCRAMP treatment group and ethanol group had low level of collagen staining in and around vimentin green staining, indicating low collagen expression in fibroblasts.

Figure 5

Intracolonic cathelicidin peptide administration reduces colonic collagen deposition in cathelicidin deficient mice with chronic TNBS colitis.

(A) Representative H&E images of colonic tissues. (B) Histology score was based on H&E staining images of colonic tissues. TNBS treatment in \( Camp^{-/-} \) mice led to increased tissue damage with significantly higher histology score (p=0.001), compared to ethanol control. Peptide treatment of mCRAMP significantly reduced histology score in \( Camp^{-/-} \) mice (p=0.04). (C) Masson Trichrome staining for collagen in colonic tissues. Collagen was stained in blue. Collagen deposited in mucosal and submucosal layer of TNBS treated \( Camp^{-/-} \) mice was reduced by mCRAMP peptide treatment. (D) Quantitative real-time RT-PCR of collagen col1a2 mRNA expression in colonic tissues of mice. TNBS treatment significantly induced colonic col1a2 mRNA (p=0.0311) expression. Intracolonic treatment of mCRAMP reduced colonic col1a2 mRNA expression in \( Camp^{-/-} \) (p=0.04) mice. (E) TNBS treatment significantly induced colonic Tnf\( \alpha \) protein (p=0.0042 in WT and p=0.0241 in \( Camp^{-/-} \) mice) expression. Intracolonic mCRAMP administration significantly reduced TNBS induced Tnf\( \alpha \) protein expression in \( Camp^{-/-} \) (p=0.0054) mice. n=6 mice per group.

Figure 6

Lentiviral cathelicidin expression reduces colonic inflammation in TNBS mediated chronic colitis in mice.
Anti-fibrogenic effects of cathelicidin in chronic colitis.

(A) Illustration of experimental plan of TNBS mediated chronic colitis with lentiviral vector protocol. Mice were injected with increasing doses of TNBS solution intracolonically once a week for 6 weeks as described in Materials and Methods. Some mice received intravenous injection of mouse cathelicidin Camp-HA expressing lentivirus or HA expressing lentivirus (control), starting from the fifth TNBS injection. Colonic changes were evaluated 1 week after the last TNBS injection. (B) Colonic Camp mRNA expression was significantly increased in the Camp-LV group (p=0.026 and p=0.0413). (C) Representative H&E images of colonic tissues. (D) Histology score was based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue damage with significantly higher histology score (p=0.001), compared to ethanol control. Treatment of Camp-LV significantly reduced histology score (p=0.0034). (E) Percent of body weight change of different groups (from week 0 to week 6). Cathelicidin expressing lentivirus infection did not alter mice body weight. n=6 mice per group.

Figure 7

Lentiviral cathelicidin expression reduces colonic collagen deposition in mice with chronic TNBS colitis.

(A) Masson Trichrome staining for collagen in colonic tissues. Collagen deposited in mucosal and submucosal layer of TNBS-treated mice was reduced by Camp expressing lentivirus treatment. (B) Fibrosis score of colonic tissues. The elevated fibrosis score of TNBS treated mice was significantly reduced by Camp expressing lentivirus treatment (p=0.0001). (C) Colonic col1a2 mRNA expression was significantly reduced in Camp-lentivirus group (p=0.0497). n=6 mice per group.

Figure 8
Anti-fibrogenic effects of cathelicidin in chronic colitis.

**Lentiviral cathelicidin expression reduces colonic inflammation in *Salmonella*-induced cecal inflammation in mice.**

(A) Illustration of experimental plan of *Salmonella* mediated cecal inflammation with lentiviral vector protocol. Mice were fed with streptomycin to reduce the microflora load in the intestine and facilitate infection. 24 hours later, the mice were inoculated with *Salmonella*. Some mice received intravenous injection of mouse cathelicidin Camp-HA-expressing lentivirus or control lentivirus on day 11. Cecal changes were evaluated on day 21. (B) Cecal Camp mRNA expression was significantly increased in the *Salmonella* infected group and was further augmented in Camp-LV group (p=0.0001 and p=0.0317). (C) Representative H&E images of colonic tissues. (D) Histology score was based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue damage with significantly higher histology score (p=0.0001), compared to ethanol control. Treatment of Camp-LV significantly reduced histology score (p=0.0001). (E) *Salmonella* infection significantly induced cecal Tnfα mRNA (p=0.0001) expression. Camp-lentivirus treatment significantly reduced *Salmonella* induced Tnfα mRNA (p=0.0107) expression. n=6 mice per group.

**Figure 9**

**Lentiviral cathelicidin expression reduces colonic collagen deposition in mice with *Salmonella*-induced cecal fibrosis.**

(A) Percent of body weight change of different groups (from day 0 to day 21). *Salmonella* or cathelicidin expressing lentiviral infection did not alter the body weight of mice. (B) Masson Trichrome staining for collagen in colonic tissues. Collagen deposited in mucosal and submucosal layers of *Salmonella* infected mice was reduced by Camp-expressing lentivirus treatment. (C) Fibrosis score of colonic tissues. The elevated fibrosis score of *Salmonella* infected mice was significantly
Anti-fibrogenic effects of cathelicidin in chronic colitis.

reduced by *Camp* expressing lentivirus treatment (p=0.0001). (D) Colonic col1a2 mRNA expression was significantly reduced in *Camp*-lentivirus group (p=0.0251). (E) Cecal Tgf-β1 mRNA expression in mice with *Salmonella* infection. *Salmonella* infection increased cecal Tgf-β1 mRNA expression (p=0.0091) but such increase was not affected by *Camp*-lentivirus. n=6 mice per group.

**Figure 10**

**Cathelicidin reduces collagen expression in human primary intestinal fibroblasts.**

(A and B) Human primary intestinal fibroblasts isolated from normal subjects were treated with TGF-β1 (50 ng/ml) and IGF-1 (10 ng/ml) or TGF-β1 (5 ng/ml) alone with or without LL-37 for 48 hours. Western blot analyses showed that TGF-β1 (p=0.0001) alone induced pro-COL1A1 protein expression. LL-37 (5 μM) significantly suppressed collagen expression in the presence of TGF-β1 alone (p=0.0001). (C) Serum-starved human primary normal intestinal fibroblasts were exposed to TFA, LL-37 (5 μM) and/or TGF-β1 (5 ng/mL) for 16 hours. LL-37 significantly inhibited collagen mRNA expression induced by TGF-β1. (D and E) Human primary intestinal fibroblasts from a CD patient were treated with TGF-β1 (50 ng/ml) and IGF-1 (10 ng/ml) together or TGF-β1 (5 ng/ml) alone with or without LL-37 (0-3 μM) for 48 hours. Western blot analyses showed that both TGF-β1 (50 ng/ml) and IGF-1 (10 ng/ml) together and TGF-β1 (5 ng/ml) alone induced pro-COL1A1 protein expression. LL-37 (3 μM) significantly suppressed collagen expression in the presence of TGF-β1 and/or IGF-1 (p=0.0001). Results are representative of 3 normal subjects and 2 CD patients.

**Figure 11**

**Cathelicidin reduces collagen expression in human CCD-18Co colonic fibroblasts.**
Anti-fibrogenic effects of cathelicidin in chronic colitis.

(A and B) Human colonic CCD-18Co fibroblasts were incubated with TGF-β1 (50 ng/ml) and IGF-1 (10 ng/ml) or TGF-β1 (5 ng/ml) alone with or without LL-37 for 8 hours. Western blot analyses showed that TGF-β1 and IGF-1 together (p=0.0001) and TGF-β1 (p=0.0001) alone induced pro-COL1A1 protein expression. LL-37 (5 μM) significantly suppressed collagen expression in the presence of TGF-β1 and IGF-1 together (p=0.0001) or TGF-β1 alone (p=0.0001). Results are representative of 3 independent experiments.

Figure 12

Anti-fibrogenic effect of cathelicidin is ERK dependent.

(A) Human primary normal intestinal fibroblasts were pretreated with DMSO, MEK1 inhibitor PD98059 (10 μM) or MEK1/2 inhibitor U0126 (10 μM) for 30 minutes, followed by LL-37 (5 μM) or TFA 0.1% and/or TGF-β1 (5 ng/ml) exposure for 48 hours. Pro-COL1A1 and GAPDH protein expression was detected by Western blot. Blockade of ERK partially reversed anti-fibrogenic effects of cathelicidin. (B) Human primary normal intestinal fibroblasts were exposed to LL-37 (1-10 μM) or TFA 0.1% and/or TGF-β1 (50 ng/ml) and IGF-1 (10 ng/ml) together or TGF-β1 (5 ng/ml) alone for 30 minutes. Cathelicidin activated ERK phosphorylation in human fibroblasts.

Figure 13

Epidermal growth factor mediated MAP kinase activation promotes anti-fibrogenic effects of cathelicidin.

(A) Serum-starved CCD-18Co fibroblasts were exposed to 5μM of LL-37 (0-30 minutes) or EGF (500 ng/mL, 30 minutes). Protein lysate was used for Western Blot analyses. LL-37 induced the phosphorylation of ERK but not EGFR. EGF (as a positive control) induced both ERK and EGFR
Anti-fibrogenic effects of cathelicidin in chronic colitis.

phosphorylation. (B) Serum-starved human primary intestinal fibroblasts were exposed to TFA, LL-37 (1-3 μM) or EGF (500 ng/mL) for 48 hours. Collagen protein expression was determined by Western Blot analysis. (C) Quantitative analysis of the Western Blot. EGF significantly promoted cathelicidin mediated inhibition of collagen expression in fibroblasts (LL-37 1μM, p=0.0001; LL-37 3μM, p = 0.0001). (D) Serum-starved CCD-18Co colonic fibroblasts were exposed to TFA, LL-37 (3-5 μM) or EGF (500 ng/mL) for 8 hours. Collagen protein expression was determined by Western Blot analysis. (E) Quantitative analysis of the Western Blot. EGF significantly promoted cathelicidin mediated inhibition of collagen expression in fibroblasts (LL-37 3μM, p=0.0001; LL-37 5μM, p = 0.0001).

Results are representative of 2 independent experiments.

Figure 14

**Cathelicidin activates ERK phosphorylation in submucosal tissue in vivo.**

(A) Immunohistochemistry of phospho-ERK in mouse colons. Both normal control and TNBS treated groups had low pERK signal in submucosal tissue. TNBS treated mice with intracolonic mCRAMP peptide administration or intravenous Camp expressing lentivirus administration had more phospho-ERK signal. (B) Immunohistochemistry of phospho-ERK in mouse cecum. Both normal control and Salmonella treated groups had low phospho-ERK signal in submucosal tissue. *Salmonella* treated mice with intravenous Camp expressing lentivirus administration had more phospho-ERK signal. n=6 mice per group.

Figure 15

**Cathelicidin does not affect TGF-β1 expression in fibroblasts.**
Anti-fibrogenic effects of cathelicidin in chronic colitis.

(A) CCD-18Co fibroblasts were treated with proinflammatory cytokine cocktail with or without LL-37 for 48 hours. TGF-β1 protein secretion from CCD-18Co was not affected by cathelicidin. (B) TGF-β1 protein remained in cell lysate was not affected by cathelicidin. Results are representative of 3 independent experiments.

REFERENCES

Anti-fibrogenic effects of cathelicidin in chronic colitis.


Anti-fibrogenic effects of cathelicidin in chronic colitis.


Anti-fibrogenic effects of cathelicidin in chronic colitis.


Figure 1

A 8 weeks old C57BL/6 mice

At the end of week 7 post-TNBS observe colon tissues

Intracolonic TFA or mCRAMP (5mg/kg every 3 days)

0.5mg/mouse 0.75mg/mouse 1mg/mouse

TNBS 0 1 2 3 4 5 6 7 wks

B

% of body weight change

p=0.045

p=0.0178

TFA mCRAMP

C H&E Staining for histological scoring (200X)

D

Histology score

TFA mCRAMP chronic TNBS colitis

p=0.001

p=0.03

E

Tfn-α mRNA expression (fold)

p=0.0344

p=0.046

TFA mCRAMP

F

Tgf-β1 mRNA expression (fold)

Mouse colons
Figure 2

Immunohistochemistry of macrophage marker F4/80
Mouse colons 200X
Figure 3

A

Masson Trichrome Staining for Collagen 200X

B

C

Colons 7 weeks

p=0.0001

p=0.0001

0.00

0.50

1.00

1.50

2.00

2.50

3.00

Colons

p=0.0376

p=0.0364

0.00

0.50

1.00

1.50

2.00

2.50

3.00

Colons

p=0.0001

p=0.0001

0.00

0.50

1.00

1.50

2.00

2.50

3.00

Colons

p=0.0376

p=0.0364

0.00

0.50

1.00

1.50

2.00

2.50

3.00

Colons

p=0.0001

p=0.0001

0.00

0.50

1.00

1.50

2.00

2.50

3.00

Colons

p=0.0376

p=0.0364

0.00

0.50

1.00

1.50

2.00

2.50

3.00

Colons
Figure 4

Immunofluorescence staining 400X
Texas red - Col1a2
FITC green - Vimentin
DAPI blue - nuclei
Figure 5

A

**Camp**⁻/⁻ TNBS

**Camp**⁻/⁻ TNBS + intracolonic mCRAMP peptide

**Camp**⁻/⁻ EtOH

H&E Staining for histological scoring (100X)

B

<table>
<thead>
<tr>
<th>Histology score</th>
<th>TNBS WT</th>
<th>TNBS Camp⁻/⁻</th>
<th>TNBS Camp⁻/⁻ mCRAMP</th>
<th>EtOH Camp⁻/⁻</th>
</tr>
</thead>
<tbody>
<tr>
<td>p</td>
<td>p=0.005</td>
<td>p=0.0042</td>
<td>p=0.0041</td>
<td>p=0.48</td>
</tr>
</tbody>
</table>

C

**Camp**⁻/⁻ TNBS

**Camp**⁻/⁻ TNBS + intracolonic mCRAMP peptide

**Camp**⁻/⁻ EtOH

E

<table>
<thead>
<tr>
<th>TNFα (pg/μg protein)</th>
<th>Wild-type</th>
<th>Camp⁻/⁻ colons</th>
<th>Camp⁻/⁻ mCRAMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>p</td>
<td>p=0.04</td>
<td>p=0.0241</td>
<td>p=0.0054</td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th>Col1a2 mRNA expression (fold)</th>
<th>TNBS WT</th>
<th>TNBS Camp⁻/⁻</th>
<th>TNBS Camp⁻/⁻ mCRAMP</th>
<th>EtOH</th>
</tr>
</thead>
<tbody>
<tr>
<td>p</td>
<td>p=0.04</td>
<td>p=0.58</td>
<td>p=0.45</td>
<td>p=0.045</td>
</tr>
</tbody>
</table>

E

<table>
<thead>
<tr>
<th>TNFα (pg/μg protein)</th>
<th>Wild-type</th>
<th>Camp⁻/⁻ colons</th>
<th>Camp⁻/⁻ mCRAMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>p</td>
<td>p=0.04</td>
<td>p=0.0241</td>
<td>p=0.0054</td>
</tr>
</tbody>
</table>
Figure 6

A
8 weeks old c57BL/6 wild-type mice

At the end of week 6 post-TNBS observe colon tissues

Camp-HA-lentivirus or HA-lentivirus
(10^7 infectious units /100 μl, i.v.)

0.5mg/mouse 0.75mg/mouse 1mg/mouse

TNBS 0 1 2 3 4 5 6 wks

B

\[ p = 0.026 \]

\[ p = 0.0413 \]

\[ \text{Camp mRNA expression (fold)} \]

\[ \text{Colons 6 weeks} \]

C
EtOH normal control

H&E staining 100X

D

\[ p = 0.0327 \]

\[ p = 0.0034 \]

\[ \text{Histology score} \]

\[ \text{Colons 6 weeks} \]

E

\[ p = 0.0001 \]

\[ p = 0.0001 \]

\[ \text{Body weight change %} \]

\[ \text{Colons 6 weeks} \]
Figure 7

A

EtOH normal control

TNBS HA-LV

TNBS Camp-LV

Masson Trichrome staining 200X

B

Fibrosis score

p=0.0001

p=0.0001

Colons 6 weeks

TNBS, TNBS Camp-LV, EtOH

C

Col1a2 mRNA expression (fold)

p=0.045

p=0.0497

TNBS HA-LV, TNBS Camp-LV, EtOH
At the end of day 21 post-infection observe cecal tissues

Salmonella SL1344
1x10^8 cfu/100μl oral gavage

Camp-lentivirus or control lentivirus
(10^7 infectious units /100 μl, i.v.)

20 mg Streptomycin oral gavage

-1 0 11 21 days

Normal control
Salmonella
Salmonella + Camp-LV

Salmonella day 21 cecum

H&E staining cecum 100X

Salmonella day 21 cecum

Tnf mRNA expression (fold)

Normal control
Salmonella
Salmonella + Camp-LV

Camp mRNA expression (fold)

Normal control
Salmonella
Salmonella + Camp-LV

Histology score
Figure 9

A) Body weight change %

- Normal Control
- Salmonella
- Salmonella + Camp-LV

B) Masson Trichrome staining 100X

- Normal Control
- Salmonella
- Salmonella + Camp-LV

C) Fibrosis score

- Normal control
- Salmonella
- Salmonella + Camp-LV

D) Col1α2 mRNA expression (fold)

- Normal Control
- Salmonella
- Salmonella + Camp-LV

E) Tgf-β1 mRNA expression (fold)

- Normal Control
- Salmonella
- Salmonella + Camp-LV
Figure 10

A

Human normal intestinal fibroblasts 48 h

LL-37 (μM) 0 1 3 5 0 1 3 5 0 1 3 5

ProCol1A1

β-tubulin

TGF-β1 50ng/ml + IGF-1 10ng/ml

B

Human normal intestinal fibroblasts 48h

Human Crohn's disease intestinal fibroblasts 48h

COL1A2 mRNA expression (fold)

Human intestinal fibroblasts 16 hours

C

D

E

TFA TGF-β1 5ng/mL TGF-β1 50ng/mL + IGF-1 10ng/mL
Figure 11

A

ProCol1A1

β-tubulin

CCD-18Co fibroblasts 8 h

B

Procollagen 1A1/β-tubulin ratio

TFA TGFβ1 5 ng/mL TGFβ1 50 ng/mL + IGF-1 10 ng/mL

LL-37 (μM) 0 1 3 5 TGFβ1 5 ng/mL + IGF-1 10 ng/mL

LL-37 (μM) 0 1 3 5

p = 0.0001

p = 0.0001

p = 0.0001

p = 0.0001

CCD-18Co fibroblasts 8 h
Figure 12

A

D= DMSO
P= PD98059
U= U0126

TFA
LL-37 5μM

D P U
D P U
D P U
D P U

TFA
5ng/ml
+ TFA
5ng/ml
+ LL-37 5μM

ProCol1A1
GAPDH

Human normal intestinal fibroblasts 48 h

B

1 2 3 4 5 6 7 8 9 10 11 12

pERK
42/44kDa

β-tubulin
60kDa

Human normal intestinal fibroblasts 30 minutes

1 TFA
2 LL-37 1μM
3 LL-37 5μM
4 LL-37 10μM
5 T+I TFA
6 T+I LL-37 1μM
7 T+I LL-37 5μM
8 T+I LL-37 10μM
9 TGF-β1 TFA
10 TGF-β1 LL-37 1μM
11 TGF-β1 LL-37 5μM
12 TGF-β1 LL-37 10μM
Figure 13

A

<table>
<thead>
<tr>
<th>minutes</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>30</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>LL-37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5μM</td>
</tr>
<tr>
<td>EGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>500ng/mL</td>
</tr>
</tbody>
</table>

pEGFR
190kDa

pERK
42/44kDa

GAPDH
35kDa

CCD-18Co Colonic Fibroblasts

B

TFA
1μM
3μM

LL-37
1μM
3μM

ProCOL1A1
190kDa

GAPDH
35kDa

Human Primary Intestinal Fibroblasts
Crohn's Disease 48hr

C

p=0.0001

D

TFA
3μM
5μM

LL-37
3μM
5μM

ProCOL1A1
190kDa

STAT5
90kDa

CCD-18Co Colonic Fibroblasts 8hr

E

p=0.0001
Figure 14

A

Normal Control

TNBS

TNBS + mCRAMP

TNBS + Camp-LV

Mouse colon pERK immunohistochemistry 400X

B

Normal Control

Salmonella

Salmonella + Camp-LV

Mouse cecum pERK immunohistochemistry 400X
Figure 15

A

Conditioned media

B

Cell lysates

TFA LL-37 5 μM
LL-37 1 μM
LL-37 5 μM
LL-37 10 μM
CCD-18Co 48 hr

P=0.0263

P=0.0019

P=0.0001

P=0.0001
Supplementary Figure

Cathelicidin did not affect cell proliferation in colonic tissues.

Immunofluorescence staining of cell proliferation marker PCNA (red), fibroblast marker vimentin (green) and nuclei DAPI (blue). In TNBS+TFA, weak red PCNA staining was observed in and around fibroblasts that were identified by green color. Overlapping images of red PCNA staining, green vimentin staining and blue nuclear staining are shown in lower right corner. All groups had low level of PCNA staining in and around vimentin green staining, indicating low cell proliferation in colonic fibroblasts.
Supplementary Figure

**TNBS + TFA**

**TNBS + mCRAMP**

**Ethanol control**

Immunofluorescence staining 400X
Texas red - PCNA
FITC green - Vimentin
DAPI blue - nuclei